Lilly maintained by Bear Stearns at peer perform

Eli Lilly & Co. was maintained by Bear Stearns analyst John Boris at a peer perform rating following published results of the long-awaited study that compared Lilly's Zyprexa to AstraZeneca plc's Seroquel for schizophrenia. Lilly shares Tuesday were down $0.66, or 1.21%, at $54.10 on volume of 4,712,700 shares versus the three-month running average of 3,656,880 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.